Novo Nordisk AS (OCSE:NOVO B, Financial) is set to release its Q4 2024 earnings on Feb 5, 2025. The consensus estimate for Q4 2024 revenue is $79.26 billion, and the earnings are expected to come in at $5.78 per share. The full year 2024's revenue is expected to be $285.57 billion and the earnings are expected to be $22.36 per share. More detailed estimate data can be found on the Forecast page.
Novo Nordisk AS (OCSE:NOVO B, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Novo Nordisk AS (OCSE:NOVO B) have declined from $287.48 billion to $285.57 billion for the full year 2024. For 2025, revenue estimates have decreased from $346.33 billion to $346.10 billion. Earnings estimates for the full year 2024 have decreased from $22.61 per share to $22.36 per share. For 2025, the earnings estimates have declined from $28.69 per share to $27.46 per share.
Novo Nordisk AS (OCSE:NOVO B, Financial) Reported History
In the previous quarter of September 30, 2024, Novo Nordisk AS's (OCSE:NOVO B) actual revenue was $71.31 billion, which missed analysts' revenue expectations of $72.47 billion by -1.59%. Novo Nordisk AS's (OCSE:NOVO B) actual earnings were $6.12 per share, which beat analysts' earnings expectations of $6.04 per share by 1.29%. After releasing the results, Novo Nordisk AS (OCSE:NOVO B) was up by 0.55% in one day.
Novo Nordisk AS (OCSE:NOVO B, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 26 analysts, the average target price for Novo Nordisk AS (OCSE:NOVO B) is $838.77 with a high estimate of $1,150.00 and a low estimate of $515.00. The average target implies an upside of 39.87% from the current price of $599.70.
Based on GuruFocus estimates, the estimated GF Value for Novo Nordisk AS (OCSE:NOVO B, Financial) in one year is $1,060.05, suggesting an upside of 76.76% from the current price of $599.70.
Based on the consensus recommendation from 27 brokerage firms, Novo Nordisk AS's (OCSE:NOVO B, Financial) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
